Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the Parkinsonian striatum

N. Ogawa, K. I. Tanaka, Masato Asanuma

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Bromocriptine, a dopamine agonist, is commonly used in combination with levodopa for the treatment of Parkinson's disease (PD). To investigate the theoretical basis of such combination therapy, we examined the effects of bromocriptine administered alone or in combination with levodopa on dopamine turnover in the striatum of hemi-parkinsonism rats. The parkinsonian striatum showed a 3.4-fold increase of dopamine turnover relative to the control striatum, as often observed in the brain of PD patients. A 7-day course of levodopa therapy markedly increased dopamine turnover in the parkinsonian striatum (53-fold of control level) than in the control striatum (5-fold of the control level). However, bromocriptine specifically and markedly suppressed the levodopa-induced abnormal activation of dopamine turnover in the Parkinsonian striatum. Our findings explain the pharmacological basis for the introduction of bromocriptine during long-term levodopa therapy.

Original languageEnglish
Pages (from-to)755-758
Number of pages4
JournalNeurochemical Research
Volume25
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Bromocriptine
Levodopa
Dopamine
Level control
Parkinson Disease
Dopamine Agonists
Parkinsonian Disorders
Brain Diseases
Therapeutics
Rats
Brain
Chemical activation
Pharmacology

Keywords

  • 6-hydroxydopamine
  • Dopamine agonist
  • Dopamine turnover
  • Dopaminergic activation
  • Hemi-parkinsonism

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry

Cite this

Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the Parkinsonian striatum. / Ogawa, N.; Tanaka, K. I.; Asanuma, Masato.

In: Neurochemical Research, Vol. 25, No. 6, 2000, p. 755-758.

Research output: Contribution to journalArticle

@article{4c0c103f783649d1bb66d19e523043c5,
title = "Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the Parkinsonian striatum",
abstract = "Bromocriptine, a dopamine agonist, is commonly used in combination with levodopa for the treatment of Parkinson's disease (PD). To investigate the theoretical basis of such combination therapy, we examined the effects of bromocriptine administered alone or in combination with levodopa on dopamine turnover in the striatum of hemi-parkinsonism rats. The parkinsonian striatum showed a 3.4-fold increase of dopamine turnover relative to the control striatum, as often observed in the brain of PD patients. A 7-day course of levodopa therapy markedly increased dopamine turnover in the parkinsonian striatum (53-fold of control level) than in the control striatum (5-fold of the control level). However, bromocriptine specifically and markedly suppressed the levodopa-induced abnormal activation of dopamine turnover in the Parkinsonian striatum. Our findings explain the pharmacological basis for the introduction of bromocriptine during long-term levodopa therapy.",
keywords = "6-hydroxydopamine, Dopamine agonist, Dopamine turnover, Dopaminergic activation, Hemi-parkinsonism",
author = "N. Ogawa and Tanaka, {K. I.} and Masato Asanuma",
year = "2000",
doi = "10.1023/A:1007530720544",
language = "English",
volume = "25",
pages = "755--758",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the Parkinsonian striatum

AU - Ogawa, N.

AU - Tanaka, K. I.

AU - Asanuma, Masato

PY - 2000

Y1 - 2000

N2 - Bromocriptine, a dopamine agonist, is commonly used in combination with levodopa for the treatment of Parkinson's disease (PD). To investigate the theoretical basis of such combination therapy, we examined the effects of bromocriptine administered alone or in combination with levodopa on dopamine turnover in the striatum of hemi-parkinsonism rats. The parkinsonian striatum showed a 3.4-fold increase of dopamine turnover relative to the control striatum, as often observed in the brain of PD patients. A 7-day course of levodopa therapy markedly increased dopamine turnover in the parkinsonian striatum (53-fold of control level) than in the control striatum (5-fold of the control level). However, bromocriptine specifically and markedly suppressed the levodopa-induced abnormal activation of dopamine turnover in the Parkinsonian striatum. Our findings explain the pharmacological basis for the introduction of bromocriptine during long-term levodopa therapy.

AB - Bromocriptine, a dopamine agonist, is commonly used in combination with levodopa for the treatment of Parkinson's disease (PD). To investigate the theoretical basis of such combination therapy, we examined the effects of bromocriptine administered alone or in combination with levodopa on dopamine turnover in the striatum of hemi-parkinsonism rats. The parkinsonian striatum showed a 3.4-fold increase of dopamine turnover relative to the control striatum, as often observed in the brain of PD patients. A 7-day course of levodopa therapy markedly increased dopamine turnover in the parkinsonian striatum (53-fold of control level) than in the control striatum (5-fold of the control level). However, bromocriptine specifically and markedly suppressed the levodopa-induced abnormal activation of dopamine turnover in the Parkinsonian striatum. Our findings explain the pharmacological basis for the introduction of bromocriptine during long-term levodopa therapy.

KW - 6-hydroxydopamine

KW - Dopamine agonist

KW - Dopamine turnover

KW - Dopaminergic activation

KW - Hemi-parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=0033871551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033871551&partnerID=8YFLogxK

U2 - 10.1023/A:1007530720544

DO - 10.1023/A:1007530720544

M3 - Article

VL - 25

SP - 755

EP - 758

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 6

ER -